Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
More GEN Content From This Contributor:
- Columns: Quo Vadis Biofuels Projects?
- Columns: Weeds and Reeds - The Invasion of the Second Generation Biofuel Crops
- Columns: International Students in the U.S. - A Diminishing Pool of Talent for Biotech?
- Columns: Thanks a lot, Bernie Madoff!
- Columns: Stimulate This!
- Columns: Biosimilar Approval in the U.S. and Europe: How Similar Are They?
- Columns: The New Face of Pharma R&D?
- Columns: Change Is the Air
- Columns: Pharma and Biotech Will Follow the Rest of the Economic Downward Trend – a Defensive Play no Longer
- Columns: Bias in Pharma Studies Published by the FDA—Shocking!!!
- Columns: Quotas for Women in Science
- Columns: The End of Nationalism (At Least in Pharma)
- Columns: The Japanese Acquisition Binge
- Columns: The Death of the Blockbuster
- Columns: Insourcing vs. outsourcing: the Roche-Genetech deal
- Columns: The Food Crisis - Exacerbated by Demand for Biofuel?
- Columns: The FDA Scale-Up: Good for Big Pharma or Not?
- Columns: Is Europe's Biotech Pipeline Empty?
- Columns: Awakening the Chinese (biotech) dragon
- Columns: No soup for you (no more) - VC-backed companies shooting for SBIR eligibility
- Columns: Big Pharma & Big Government = Big Profits?
- Columns: Post-doctoral paupers
- Columns: The Valley of Death